Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) cause facial fat atrophy, sagging, and wrinkling ("Ozempic face") by inhibiting adipocyte differentiation and promoting fibrotic transformation of dWAT.

If using GLP-1RAs, be aware that facial fat loss and skin aging ('Ozempic face') are common side effects. Consider proactive skin care or aesthetic interventions (like fat grafting or regenerative fillers) to counteract fat loss and fibrosis. Monitor facial changes and discuss mitigation strategies with your provider.

Hypertrophic (large) adipocytes promote skin aging by secreting proinflammatory cytokines, downregulating collagen/elastin, and upregulating MMPs, whereas small healthy adipocytes promote skin health via adiponectin.

Maintain a healthy weight to avoid hypertrophic (large) fat cells, which promote skin aging through inflammation and collagen breakdown. Focus on strategies that promote small, healthy fat cells, which support skin structure via adiponectin.

Chronic psychological or physiological stress contributes to severe disease susceptibility by increasing cortisol, which suppresses immune function (specifically secretory IgA) and promotes dysbiosis, thereby increasing vulnerability to infection.

Manage chronic stress through mind-body interventions like diaphragmatic breathing or other relaxation techniques, as high stress levels can suppress your immune system and disrupt your gut health, making you more vulnerable to infections.

Long-term adherence to low-carbohydrate diets may attenuate weight loss benefits and potentially increase LDL cholesterol in some individuals, raising cardiovascular risk concerns.

While LCDs work well for short-term weight loss, be aware that benefits may diminish after a year, and some people see their bad cholesterol (LDL) rise. Regular monitoring of lipids and liver health is essential if you stay on this diet long-term.

The weight loss benefit of tirzepatide over semaglutide is significantly attenuated or absent in patients with type 2 diabetes compared to those without diabetes.

For patients with diabetes, the weight loss advantage of tirzepatide over semaglutide seen in non-diabetics may not be present. Consult your doctor to manage expectations regarding weight loss if you have diabetes.

The efficacy of low carbohydrate diets for diabetes remission is markedly reduced in patients who are using insulin.

If you are using insulin for type 2 diabetes, a low carbohydrate diet can still help, but the chances of achieving full remission are lower than for those not using insulin. You may need to work more closely with your healthcare provider to adjust your insulin dosage as your blood sugar improves.

Short-chain fatty acids (SCFA) produced by gut microbiota from flavonoid and fiber fermentation influence energy metabolism, glucose-insulin homeostasis, and inflammatory pathways, with effects mediated by G-protein-coupled receptors (GPR).

Support your gut microbiota with fiber and flavonoid-rich foods to promote the production of short-chain fatty acids (SCFA). These byproducts help regulate blood sugar, energy expenditure, and inflammation.

Obesity impairs the efficacy of influenza vaccination, resulting in a higher incidence of influenza-like illness despite vaccination, suggesting similar immune evasion may occur with other vaccines.

Obesity can reduce how well your flu shot works, making you twice as likely to get sick compared to non-obese vaccinated people. Still get vaccinated, but be aware you may need extra precautions or discuss high-dose options with your doctor.

Genetic variability in the GLP1R gene can lead to non-response to GLP-1 receptor agonists in some patients with T2DM and obesity.

Some patients with T2DM and obesity do not respond well to GLP-1 receptor agonists due to genetic factors. If you are not seeing results, genetic variability in the GLP-1 receptor might be a cause. Discuss this with your healthcare provider to explore other treatment options or lifestyle interventions.

GLP-1 receptor agonists delay gastric emptying and increase the risk of pulmonary aspiration during general anesthesia, necessitating specific peri-operative management strategies.

If you take a GLP-1 drug (like Ozempic, Wegovy, or Trulicity) and have surgery, tell your anesthesiologist. You likely need to stop the drug for a specific time before surgery (often 3 half-lives, e.g., 1 week for weekly drugs) to prevent stomach contents from entering your lungs while asleep. Do not assume standard fasting rules apply; your stomach may still be full even if you haven't eaten for 12 hours.

Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.

Semaglutide helps your body use insulin better by activating specific cellular pathways (AMPK/SIRT1) that move glucose into muscles and fat cells. This reduces insulin resistance, a key factor in type 2 diabetes and obesity.

Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.

GLP-1 drugs might reduce the 'high' or addictive feeling associated with nicotine, which could make it easier for smokers to quit or use nicotine-based therapies without the usual addiction risks.

Inhibition of the p38 MAPK pathway in white adipose tissue promotes the reprogramming of white adipocytes to beige adipocytes, leading to resistance against diet-induced obesity.

Research suggests that targeting specific signaling pathways like p38 MAPK could potentially help convert energy-storing white fat into energy-burning beige fat, offering a potential future therapeutic strategy for obesity.

Promoting adipogenesis (the creation of new, functional adipocytes) through therapeutic agents can improve lipid storage capacity and prevent the transition from MHO to MUO by avoiding adipocyte dysfunction, hypoxia, and inflammation.

Current lifestyle interventions do not directly target adipogenesis. However, maintaining a healthy weight and avoiding excessive fat accumulation may help preserve adipocyte function. Future therapies may target transcription factors like PPAR-γ to promote healthy fat storage.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe food aversion, dehydration, and acute kidney injury when used without intensive clinical monitoring.

If you are taking GLP-1 agonists (like Ozempic or Mounjaro), do not use them without regular medical supervision. Watch for signs of extreme food aversion, dehydration, or rapid weight loss. If you experience severe side effects like kidney issues or inability to eat, contact your doctor immediately. These drugs are powerful and require monitoring, especially if you have a history of eating disorders or have had bariatric surgery.

Individuals with the FADS haplotype D (high-efficiency LC-PUFA biosynthesis) face increased susceptibility to severe COVID-19 when consuming a modern diet high in omega-6 fatty acids, due to the resulting proinflammatory state and cytokine storm.

If you have a family history of high inflammation or belong to a group with higher prevalence of FADS haplotype D (often correlated with African or Hispanic ancestry), prioritize balancing your fatty acid intake. Reduce oils high in omega-6 (corn, soybean, sunflower) and increase omega-3 sources (fish, flax, walnuts) to lower the risk of severe inflammatory responses to infections like COVID-19.

High intake of omega-6 fatty acids and fructose, combined with obesity, creates a chronic low-grade inflammatory state that increases susceptibility to and severity of COVID-19.

To reduce the risk of severe illness from respiratory infections, focus on reducing ultra-processed foods, sugary drinks, and seed oils. Prioritize whole foods, fruits, vegetables, and healthy fats to lower chronic inflammation, which is a key driver of disease severity.

GIP (Glucose-dependent Insulinotropic Polypeptide) promotes fat storage and has unfavorable vascular effects, contrasting with the protective effects of GLP-1.

High-GI foods trigger GIP, which may promote fat storage and inflammation. Avoiding high-GI foods helps minimize GIP release, potentially aiding in weight management and reducing cardiovascular risk factors associated with GIP, such as hepatic steatosis and atherosclerosis.

Environmental cold exposure and specific bioactive compounds (e.g., resveratrol, menthol) induce the browning of white adipose tissue (WAT) and activation of brown adipose tissue (BAT), thereby increasing energy expenditure and improving metabolic health.

You can potentially boost your metabolism by exposing yourself to cold or consuming specific compounds like resveratrol or menthol. These actions encourage your body to convert energy-storing white fat into energy-burning brown or beige fat. While cold exposure is effective, it may be uncomfortable, so exploring dietary sources of these compounds or exercise-induced browning might be more sustainable alternatives for long-term metabolic health.

Obesity and aging are associated with the 'whitening' of brown adipose tissue, characterized by lipid accumulation, loss of mitochondria, and impaired thermogenesis, which contributes to metabolic dysfunction.

As you age or gain weight, your body's ability to burn fat as heat (via brown fat) naturally declines, contributing to further weight gain and metabolic issues. This process is called 'whitening.' While you cannot reverse aging, you can potentially slow this decline by maintaining physical activity and exposing yourself to cold, which may help preserve your brown fat function and metabolic health.

Aging blunts the ability for serial sarcomerogenesis (addition of new sarcomeres in series), leading to shortened fascicle length and impaired muscle mechanical function, primarily due to age-related impairments in mechanotransduction pathways like mTOR, IGF-1, and SRF signaling.

For older adults, maintaining or improving muscle function may require specific interventions that promote muscle lengthening, such as eccentric resistance training or chronic stretching. While muscle mass loss is common, the shortening of muscle fascicles (due to loss of serial sarcomeres) contributes significantly to stiffness and reduced power. Targeted training that emphasizes the lengthening phase of movements may help mitigate these age-related architectural changes, though the response may be slower or smaller than in younger individuals.

Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.

Understand that exercise is a systemic therapy. When you move, your muscles release signals that improve the health of your heart, brain, and fat tissue, not just the muscles themselves.

Tirzepatide (TRZD) may increase the risk of cancer progression, specifically pancreatic and medullary thyroid cancer (MTC), through GLP-1R/GIPR-mediated activation of oncogenic pathways (PI3K/Akt/mTOR, Ras-Raf-ERK) and calcitonin release, particularly in patients with prior pancreatitis or family history of MTC.

If you have a personal or family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), you should not use Tirzepatide. If you have a history of pancreatitis, use with caution and monitor for symptoms. For other diabetic patients, the long-term cancer risk is currently unknown, but the drug is approved for weight loss and glucose control. Discuss your specific cancer history with your provider before starting.

Tirzepatide (TRZD) and other GLP-1R/GIPR agonists may exhibit anti-cancer properties by sensitizing cancer cells to chemotherapy, inducing apoptosis, and inhibiting proliferation via pathways like PI3K/Akt/mTOR and AMPK, particularly in pancreatic, breast, and colorectal cancers.

Current research shows that drugs like Liraglutide and Exenatide can kill cancer cells or make chemo work better in lab mice. However, there is no proof yet that Tirzepatide does this in humans. Do not use these drugs as a cancer treatment outside of clinical trials.